RxDoctor Payments Data

Andrea Dellaria, MD

Neurology · Lake Barrington, ILNPI 1982036182

Payments from drug & device makers

$6,113in general payments, 2019–2025

Across 317 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AbbVie$1K
  • Pfizer$588
  • Bristol Myers Squibb$519
  • TG Therapeutics, Inc.$324
  • Biogen$220
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$6,108100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,113 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$338,461
Medicare patients
496
Services billed
75,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin22$227,961
Memantine Hcl378$13,347
Donepezil Hcl528$6,396
Levetiracetam108$3,181
RivastigmineRivastigmine Tartrate17$2,894
Aspirin-Dipyridamole ErAspirin/Dipyridamole12$2,886
Carbamazepine ErCarbamazepine16$2,444
Gabapentin110$1,695
Sertraline Hcl132$1,221
Oxcarbazepine18$1,156
Pregabalin25$1,121
Quetiapine Fumarate74$1,097
Memantine Hcl ErMemantine Hcl27$940
Duloxetine Hcl33$882
Carbidopa-LevodopaCarbidopa/Levodopa36$837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$212$227,96122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 790 neurology providers in Illinois.

Other neurology in Lake Barrington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →